<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002619</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000063964</org_study_id>
    <secondary_id>NYU-97-8</secondary_id>
    <secondary_id>MSKCC-94101</secondary_id>
    <secondary_id>NCI-V94-0594</secondary_id>
    <nct_id>NCT00002619</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors</brief_title>
  <official_title>A TRIAL OF INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RECONSTITUTION FOR PATIENTS BETWEEN SIX AND SIXTY YEARS OF AGE, WITH NON-PROGRESSIVE GLIOBLASTOMA MULTIFORME OR DIFFUSE INTRINSIC BRAINSTEM TUMORS, FOLLOWING INITIAL LOCAL-FIELD IRRADIATION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Bone marrow or peripheral stem cell transplantation may be able to&#xD;
      replace immune cells that were destroyed by chemotherapy used to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by autologous&#xD;
      bone marrow or peripheral stem cell transplantation in treating patients with glioblastoma&#xD;
      multiforme or brain stem tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Estimate the overall survival, progression-free interval, and time to&#xD;
      progression or recurrence in patients with nondisseminated glioblastoma multiforme or diffuse&#xD;
      intrinsic brain stem tumors that are nonprogressive following surgery (if feasible) and&#xD;
      involved-field irradiation and treated with intensive chemotherapy followed by autologous&#xD;
      peripheral blood stem cell (PBSC) or autologous bone marrow (ABM) rescue. II. Estimate the&#xD;
      toxicity of myeloablative chemotherapy with thiotepa (TSPA) followed by carboplatin (CBDCA)&#xD;
      in these patients. III. Evaluate the pharmacokinetic interactions of high-dose CBDCA, TSPA,&#xD;
      and triethylenephosphoramide (a metabolite of TSPA) and any impact on subsequent toxicity.&#xD;
      IV. Evaluate the effectiveness of autologous stem cells in restoring hematopoiesis following&#xD;
      myeloablative therapy.&#xD;
&#xD;
      OUTLINE: All patients undergo bone marrow or stem cell harvest (investigator option) no later&#xD;
      than 12 weeks after completion of radiotherapy. The following acronyms are used: ABM&#xD;
      Autologous Bone Marrow CBDCA Carboplatin, NSC-241240 G-CSF Granulocyte Colony-Stimulating&#xD;
      Factor (Amgen), NSC-614629 PBSC Peripheral Blood Stem Cells TSPA Thiotepa, NSC-6396 2-Drug&#xD;
      Myeloablative Chemotherapy followed by Hematopoietic Rescue. TSPA; CBDCA; followed by ABM or&#xD;
      PBSC; G-CSF.&#xD;
&#xD;
      PROJECTED ACCRUAL: 60 patients will be entered over 3 years. If more than 5 patients on any&#xD;
      arm experience treatment-related mortality, accrual will be discontinued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1994</start_date>
  <primary_completion_date type="Actual">April 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Glioblastoma multiforme (GBM) or brain stem tumor following&#xD;
        surgery (if feasible) and local radiotherapy, as follows: Pathologically confirmed primary&#xD;
        GBM Gliosarcomas and multifocal GBM eligible Unbiopsied diffuse intrinsic pontine tumors&#xD;
        Nonenhancing with gadolinium on MRI T1 hypodense and T2 hyperdense No recurrent or&#xD;
        progressing disease following radiotherapy No leptomeningeal dissemination by radiographic&#xD;
        evaluation including head MRI and either whole-spine MRI with gadolinium or myelogram&#xD;
        Positive CSF cytology alone allowed No extraneural metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 6 to under 60 Performance status: Karnofsky 70%-100% (over&#xD;
        age 16) Lansky 70%-100% (ages 6-16) Hematopoietic: Not specified Hepatic: Bilirubin less&#xD;
        than 2.0 mg/dL AST or ALT less than 5 times normal PT and aPTT normal (consult with&#xD;
        principal investigator if abnormal) Renal: Creatinine clearance at least 50 mL/min/1.73 sqm&#xD;
        Cardiovascular: No evidence of myocardial infarction or ischemia on EKG Other: No active&#xD;
        infection at time of leukapheresis Able to tolerate anticoagulation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Radical surgery and involved-field radiotherapy (at least 4,500&#xD;
        cGy) completed within 6 weeks prior to entry Second surgical debulking following&#xD;
        radiotherapy strongly encouraged for patients with residual tumor mass or suspected&#xD;
        radionecrosis Requirement for surgery waived for unresectable brainstem tumors No prior&#xD;
        chemotherapy except corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan L. Finlay, MB, ChB</last_name>
    <role>Study Chair</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaplan Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2000</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2004</study_first_posted>
  <last_update_submitted>November 8, 2012</last_update_submitted>
  <last_update_submitted_qc>November 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

